Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

OBJECTIVES: To evaluate the recapture of response with open-label (OL) ixekizumab (IXE) retreatment at week 104 in patients with axial spondyloarthritis who flared after withdrawal of IXE therapy. METHODS: COAST-Y (NCT03129100) is a phase III extension study that included a double-blind, placebo-con...

Descripción completa

Detalles Bibliográficos
Autores principales: Landewé, Robert B M, Poddubnyy, Denis, Rahman, Proton, Van den Bosch, Filip E, Bolce, Rebecca, Liu Leage, Soyi, Lisse, Jeffrey R, Park, So Young, Gensler, Lianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887347/
https://www.ncbi.nlm.nih.gov/pubmed/36100350
http://dx.doi.org/10.1136/ard-2022-222731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887347/
https://www.ncbi.nlm.nih.gov/pubmed/36100350
http://dx.doi.org/10.1136/ard-2022-222731

Ejemplares similares